The time aspect in storing vitrified blastocysts: its impact on survival rate, implantation potential and babies born

Wirleitner, Barbara; Vanderzwalmen, Pierre; Bach, Magnus; Baramsai, B.; Neyer, Anton; Schwerda, Delf; Schuff, Maximilian; Spitzer, D; Stecher, Astrid; Zintz, Martin; Zech, Nicolas H.

doi:10.1093/humrep/det361

Cited by 49 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 A single-center study conducted in Japan, including more than 8,700 cycles, demonstrated that cryostorage of vitrified blastocysts in open devices (Cryotop) up to 8 years did not impact clinical and neonatal outcomes following single vitrified/warmed blastocyst transfer. 38 Similar conclusions were reached in the study of Wirleitner et al, 39 which included 603 single and double blastocyst transfers and 1,077 blastocysts vitrified in an "aseptic" closed device (Vitrisafe). The results showed that storage time of up to 6 years following vitrification did not have a negative impact on blastocyst survival and implantation, or congenital malformation rates in resulting newborns.…”

Section: Reduced or Lost Viability: (I) Duration Of Storagesupporting

confidence: 62%

Human Reproductive Cell Cryopreservation, Storage, Handling, and Transport: Risks and Risk Management

Alikani

Parmegiani

2018

Semin Reprod Med

View full text Add to dashboard Cite

Millions of human oocytes and embryos are stored in thousands of locations across the globe. This inventory continues to grow as cryopreservation becomes more successful and more widely applied. The results of studies assessing pregnancy and neonatal outcomes following frozen embryo transfer (FET) have been encouraging, showing lower incidences of small for gestational age neonates and preterm birth compared with fresh transfers. However, many of these studies have also shown that the odds of large for gestational age births and macrosomia are higher after FET. The origin of these conditions remains unclear. Cryostorage presents many potential risks to the cryopreserved cells/tissues, including loss of viability and contamination, but risks are faced also by care providers—for example, injury and financial liability—and by patients—for example, accidental loss of their reproductive tissues, the burden of embryos they no longer wish to use and failing to meet their contractual obligations. Studies are urgently needed to explore and understand all dimensions of cryostorage to help ART clinics develop effective strategies to manage associated risks. The future of cryostorage, as for many other areas of ART and medicine, is automation.

show abstract

Section: Reduced or Lost Viability: (I) Duration Of Storagesupporting

confidence: 62%

Human Reproductive Cell Cryopreservation, Storage, Handling, and Transport: Risks and Risk Management

Alikani

Parmegiani

2018

Semin Reprod Med

View full text Add to dashboard Cite

show abstract

“…Liquid nitrogen (À196 C) is the preferred environment for long-term storage. Embryos can be stored in liquid nitrogen for long periods of time without affecting the embryo survival rates or pregnancy outcomes [40].…”

Section: Cryopreservation Methodsmentioning

confidence: 99%

Embryo Cryopreservation in Breast Cancer Patients

Bedoschi

Oktay

2016

Gonadal Tissue Cryopreservation in Fertility Preservation

View full text Add to dashboard Cite

Breast cancer is the second most common type of cancer expected to occur in women in 2014, accounting for 29 % of incident cases among women. Approximately 11 % of all breast cancer cases occur in women <45 years. Most of those patients are likely to undergo adjuvant systemic chemotherapy with a significant impact on ovarian reserve and future reproductive potential. Embryo cryopreservation is the most established technique for fertility preservation. This procedure is an attractive strategy for fertility preservation in reproductive age breast cancer patients with available partner or willing to use donor semen. Some special considerations should be given to ovarian stimulation for fertility preservation in breast cancer patients. The development of ovarian stimulation protocols using aromatase inhibitor combined with gonadotropin appears to be effective and safe for breast cancer patients. In this chapter, we will appraise and summarize the current state of embryo cryopreservation in breast cancer patients in order to provide a better understanding of the efficacy and safety of this fertility preservation technique. Keywords Embryo cryopreservation • Breast cancer • Fertility preservation • Ovarian stimulation • Letrozole IntroductionBreast cancer is a major public health problem in the United States and lives up to large investments in research, prevention, early diagnosis, and treatment.Breast cancer is the second most common type of cancer expected to occur in women in 2014, accounting for 29 % (232,670) of incident cases among women [1]. The relatively stable incidence rates during the past 5 years for which there are data reflect improvements in cancer control and screening methods. At the same time, the detection of cancer at an early stage and the development of the treatment

show abstract

“…63 A major retrospective study on over 600 FET cycles using human blastocysts frozen in a closed vitrification system similarly found no differences in embryo viability, clinical pregnancy/ live birth rates or birth weight, gestational age, or the incidence of malformations based on stratified storage length between 90 days and 72 months. 64 Recently, a very large cohort study examined the effect of storage length based on almost 9,000 FET cycles using single human blastocysts vitrified in an open system. 57 Storage length period varied between less than 2 months to over 13 months with the longest storage being 8 years.…”

Section: Storage Duration and Potential Consequencesmentioning

confidence: 99%

Life Interrupted: The Nature and Consequences of Cryostasis

Malter

2018

Semin Reprod Med

View full text Add to dashboard Cite

Cryopreservation and associated cryostorage has become a well-established technique in both basic and clinical science. When the potentially lethal consequences of freezing itself are ameliorated, existence at cryogenic temperatures seems to be a form of true viable stasis that can persist for long periods of time. Natural cryopreservation and revival after long-term periods in cryostasis is reality in many species. While some evidence exists for imperfections in artificial cryopreservation protocols and storage, these protocols are for the most part successful and compatible with efficient restoration of vitality in a variety of biomaterial after freezing. Clinical protocols in use for cryopreserving and storing gametes and embryos in human-assisted reproduction are similarly well proven and supported by a large body of basic science and clinical outcome data.

show abstract

The time aspect in storing vitrified blastocysts: its impact on survival rate, implantation potential and babies born

Cited by 49 publications

References 31 publications

Human Reproductive Cell Cryopreservation, Storage, Handling, and Transport: Risks and Risk Management

Human Reproductive Cell Cryopreservation, Storage, Handling, and Transport: Risks and Risk Management

Embryo Cryopreservation in Breast Cancer Patients

Life Interrupted: The Nature and Consequences of Cryostasis

Contact Info

Product

Resources

About